@article{fdi:010059619,
  title = {{A}nti-pfs25 human plasma reduces transmission of {P}lasmodium falciparum isolates that have diverse genetic backgrounds},
  author = {{D}a, {D}. {F}. and {D}ixit, {S}. and {S}attabonkot, {J}. and {M}u, {J}. {B}. and {A}bate, {L}uc and {R}amineni, {B}. and {O}uedraogo, {J}. {B}. and {M}ac{D}onald, {N}. {J}. and {F}ay, {M}. {P}. and {S}u, {X}. {Z}. and {C}ohuet, {A}nna and {W}u, {Y}. {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{P}fs25 is a leading candidate for a malaria transmission-blocking vaccine whose potential has been demonstrated in a phase 1 trial with recombinant {P}fs25 formulated with {M}ontanide {ISA}51. {B}ecause of limited sequence polymorphism, the anti-{P}fs25 antibodies induced by this vaccine are likely to have transmission-blocking or -reducing activity against most, if not all, field isolates. {T}o test this hypothesis, we evaluated transmission-blocking activities by membrane feeding assay of anti-{P}fs25 plasma from the {P}fs25/{ISA}51 phase 1 trial against {P}lasmodium falciparum parasites from patients in two different geographical regions of the world, {T}hailand and {B}urkina {F}aso. {I}n parallel, parasite isolates from these patients were sequenced for the {P}fs25 gene and genotyped for seven microsatellites. {T}he results indicate that despite different genetic backgrounds among parasite isolates, the {P}fs25 sequences are highly conserved, with a single nonsynonymous nucleotide polymorphism detected in 1 of 41 patients in {T}hailand and {B}urkina {F}aso. {T}he anti-{P}fs25 immune plasma had significantly higher transmission-reducing activity against parasite isolates from the two geographical regions than the nonimmune controls ({P} < 0.0001).},
  keywords = {},
  booktitle = {},
  journal = {{I}nfection and {I}mmunity},
  volume = {81},
  numero = {6},
  pages = {1984--1989},
  ISSN = {0019-9567},
  year = {2013},
  DOI = {10.1128/iai.00016-13},
  URL = {https://www.documentation.ird.fr/hor/fdi:010059619},
}